GOLGA6L Activators
GOLGA6L activators are small molecules that play a crucial role in modulating the activity of GOLGA6L, a Golgi apparatus-associated protein. These activators exert their influence through indirect means, either by inhibiting specific signaling pathways or cellular processes that regulate GOLGA6L expression or by preventing its downregulation. Notably, SB431542, a TGF-β receptor inhibitor, indirectly activates GOLGA6L by suppressing the TGF-β signaling pathway. This inhibition prevents GOLGA6L downregulation, allowing sustained GOLGA6L activity and influencing cellular processes related to GOLGA6L through the modulation of TGF-β-mediated signaling.
Similarly, inhibitors targeting pathways such as p38 MAP kinase (BIRB 796, ZCL278), MAPK/ERK (PD98059, FR180204, U0126), JNK (JNK Inhibitor VIII, SP600125), PI3K/AKT (LY294002, Wortmannin), and mTOR (AZD8055, Rapamycin) indirectly activate GOLGA6L by preventing its downregulation. These compounds exhibit their effects by disrupting specific signaling cascades, ultimately promoting sustained GOLGA6L activity. For instance, BIRB 796, a p38 MAP kinase inhibitor, dampens p38 MAP kinase signaling, preventing GOLGA6L downregulation and influencing cellular processes related to GOLGA6L through modulation of the p38 MAP kinase pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly activates GOLGA6L by suppressing the TGF-β signaling pathway. This inhibition prevents GOLGA6L downregulation, allowing sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of TGF-β-mediated signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796, a p38 MAP kinase inhibitor, indirectly activates GOLGA6L by dampening p38 MAP kinase signaling. This inhibition prevents GOLGA6L downregulation, facilitating sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the p38 MAP kinase pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly activates GOLGA6L by inhibiting the MAPK/ERK pathway. This inhibition prevents GOLGA6L downregulation, promoting sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the MAPK/ERK signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates GOLGA6L by suppressing the PI3K/AKT pathway. This inhibition prevents GOLGA6L downregulation, fostering sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the PI3K/AKT signaling pathway. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII indirectly activates GOLGA6L by inhibiting the JNK pathway. This inhibition prevents GOLGA6L downregulation, facilitating sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the JNK signaling pathway. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, a dual mTOR inhibitor, indirectly activates GOLGA6L by suppressing mTOR signaling. This inhibition prevents GOLGA6L downregulation, promoting sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the mTOR signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly activates GOLGA6L by suppressing mTOR signaling. This inhibition prevents GOLGA6L downregulation, fostering sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the mTOR signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly activates GOLGA6L by inhibiting the JNK pathway. This inhibition prevents GOLGA6L downregulation, facilitating sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly activates GOLGA6L by suppressing the PI3K/AKT pathway. This inhibition prevents GOLGA6L downregulation, promoting sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the PI3K/AKT signaling pathway. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204, an ERK inhibitor, indirectly activates GOLGA6L by inhibiting the MAPK/ERK pathway. This inhibition prevents GOLGA6L downregulation, fostering sustained GOLGA6L activity. The compound influences cellular processes related to GOLGA6L through modulation of the MAPK/ERK signaling cascade. | ||||||